IL-18 binding protein (IL-18BP) in inflammatory diseases
The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.
1. A method for treating an IL-18 associated disease or disorder in a subject, wherein the IL-18 associated disease or disorder is selected from chronic obstructive pulmonary disease (COPD) or Adult-onset Still's disease (AOSD), the method comprising administering to said subject a therapeutically effective amount of an IL-18 inhibitor, wherein the IL-18 inhibitor is an IL-18 binding protein (IL-18BP).
2. The method of claim 1 , wherein the subject has abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject.
3. The method of claim 1 , wherein said IL-18 associated disease or disorder is chronic obstructive pulmonary disease (COPD).
4. The method of claim 1 , wherein said IL-18 associated disease or disorder is Adult-onset Still's disease (AOSD).
5. The method of claim 1 , wherein administration of the IL-18 inhibitor leads to inhibition of increased expression of IFNγ, IL-13 or IL-17A in treated subjects compared to untreated subjects suffering from said disease or disorder.
6. The method of claim 2 , wherein said abnormal level of free IL-18 in the body fluids exceeds the level in body fluids of a healthy control subject by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%.
7. The method of claim 6 , wherein said abnormal levels of free IL-18 are elevated levels of free IL-18, wherein the elevated levels of free IL-18 are ≥5 pg/mL; and wherein the body fluid is serum.
8. The method of claim 1 , wherein the IL-18BP is a human IL-18BP (hIL-18BP).
9. The method of claim 8 , wherein the hIL-18BP is a recombinant human IL-18BP.
10. The method of claim 1 , wherein the IL-18BP is an isoform of IL-18BP.
11. The method of claim 1 , wherein the subject is diagnosed with having abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject, wherein the level of free IL-18 in the body fluids of the subjects has been determined by an immunoassay.
12. The method of claim 11 , wherein the immunoassay comprises an IL-18BP as a capturing molecule.
13. The method of claim 12 , wherein the IL-18BP is a human IL-18BP (hIL-18BP).
14. The method of claim 13 , wherein the hIL-18BP is a recombinant hIL-18BP.
15. The method of claim 12 , wherein the IL-18BP is an isoform of IL-18BP.
16. The method of claim 11 , wherein the abnormal levels of free IL-18 and/or abnormal ratio of free IL-18/IL-18BP in the body fluids compared to the levels in the body fluids of a healthy control subject have been determined by a method comprising the steps of:
a) bringing a sample or a specific body part or body area suspected to contain free IL-18 into contact with an IL-18 binding molecule, which specifically binds to free IL-18, but not to IL-18 bound in a complex;
b) allowing the IL-18 binding molecule to bind to free IL-18;
c) detecting the binding of IL-18 to the IL-18 binding molecule and determining the amount of free IL-18 and/or the ratio of free IL-18/IL-18BP in the sample.
17. The method of claim 11 , wherein the level of free IL-18 in the body fluids of the subjects has not been determined by calculation based on the Law of Mass Action.
18. The method of claim 11 , wherein said abnormal level of free IL-18 in the body fluids exceeds the level in body fluids of a healthy control subject by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%.